The objective of the LORD Trial is to assess whether atorvastatin 10mg can slow the progression of CKD. Measures of oxidative stress and inflammation will be used to assess whether these are concomitantly affected by this statin treatment. If statins slow the progression of CKD, then most CKD patients may benefit from this treatment. Previous studies have been conducted in this area but have been either smaller, open labeled or short duration. Other studies, such as the SHARP study, seek to assess the same question however they include the cholesterol absorption inhibitor ezetimibe in the treatment group, which may confuse the nature of the potential effective agent. The measure of eGFR every three months during the three-year trial is another strength of this protocol. We predict atorvastatin will slow the progression of CKD.
Pfizer Pharmaceuticals provided the atorvastatin and placebo. Lisa Anderson and Marianne Smith are Trial Coordinators. Matthew Fassett and Krystal Chugg constructed the Database.Funding information
The Clifford Craig Medical Research Trust is funding this study.
Robert G Fassett, Renal Research Tasmania, Launceston General Hospital, Charles St., Launceston, Tasmania, 7005, Australia; Email: email@example.com
BMC Nephrology © 2008 Fassett et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cite this: The Lipid Lowering and Onset of Renal Disease (LORD) Trial: a Randomized Double Blind Placebo Controlled Trial Assessing the Effect of Atorvastatin on the Progression of Kidney Disease - Medscape - Mar 18, 2008.